XERS Valuation

Xeris Biopharma Holdings Inc

Add to Watchlist

Advanced Chart

9.900

+0.2(2.062%)1D

XERS Relative Valuation

XERS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XERS is overvalued; if below, it's undervalued.

Historical Valuation

Xeris Biopharma Holdings Inc (XERS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 9.70 is considered Overvalued compared with the five-year average of -10.29. The fair price of Xeris Biopharma Holdings Inc (XERS) is between 5.83 to 7.20 according to relative valuation methord. Compared to the current price of 9.90 USD , Xeris Biopharma Holdings Inc is Overvalued By 37.45%.

Relative Value

Fair Zone

5.83-7.20

Current Price：9.90

37.45%

Overvalued

129.33

Trailing

Forward

33.51

EV/EBITDA

Xeris Biopharma Holdings Inc. (XERS) has a current EV/EBITDA of 33.51. The 5-year average EV/EBITDA is -16.22. The thresholds are as follows: Strongly Undervalued below -241.22, Undervalued between -241.22 and -128.72, Fairly Valued between 96.28 and -128.72, Overvalued between 96.28 and 208.78, and Strongly Overvalued above 208.78. The current Forward EV/EBITDA of 33.51 falls within the Historic Trend Line -Fairly Valued range.

52.87

EV/EBIT

Xeris Biopharma Holdings Inc. (XERS) has a current EV/EBIT of 52.87. The 5-year average EV/EBIT is -3.44. The thresholds are as follows: Strongly Undervalued below -95.09, Undervalued between -95.09 and -49.27, Fairly Valued between 42.39 and -49.27, Overvalued between 42.39 and 88.21, and Strongly Overvalued above 88.21. The current Forward EV/EBIT of 52.87 falls within the Overvalued range.

9.70

Xeris Biopharma Holdings Inc. (XERS) has a current PS of 9.70. The 5-year average PS is 2.11. The thresholds are as follows: Strongly Undervalued below 0.43, Undervalued between 0.43 and 1.27, Fairly Valued between 2.95 and 1.27, Overvalued between 2.95 and 3.79, and Strongly Overvalued above 3.79. The current Forward PS of 9.70 falls within the Strongly Overvalued range.

60.71

P/OCF

Xeris Biopharma Holdings Inc. (XERS) has a current P/OCF of 60.71. The 5-year average P/OCF is 61.85. The thresholds are as follows: Strongly Undervalued below -596.45, Undervalued between -596.45 and -267.30, Fairly Valued between 391.00 and -267.30, Overvalued between 391.00 and 720.15, and Strongly Overvalued above 720.15. The current Forward P/OCF of 60.71 falls within the Historic Trend Line -Fairly Valued range.

61.67

P/FCF

Xeris Biopharma Holdings Inc. (XERS) has a current P/FCF of 61.67. The 5-year average P/FCF is -29.99. The thresholds are as follows: Strongly Undervalued below -285.05, Undervalued between -285.05 and -157.52, Fairly Valued between 97.54 and -157.52, Overvalued between 97.54 and 225.07, and Strongly Overvalued above 225.07. The current Forward P/FCF of 61.67 falls within the Historic Trend Line -Fairly Valued range.

Xeris Biopharma Holdings Inc (XERS) has a current Price-to-Book (P/B) ratio of -81.01. Compared to its 3-year average P/B ratio of -11.48 , the current P/B ratio is approximately 605.46% higher. Relative to its 5-year average P/B ratio of -11.14, the current P/B ratio is about 626.91% higher. Xeris Biopharma Holdings Inc (XERS) has a Forward Free Cash Flow (FCF) yield of approximately -1.07%. Compared to its 3-year average FCF yield of -19.78%, the current FCF yield is approximately -94.58% lower. Relative to its 5-year average FCF yield of -25.53% , the current FCF yield is about -95.80% lower.

-81.01

P/B

Median3y

-11.48

Median5y

-11.14

-1.07

FCF Yield

Median3y

-19.78

Median5y

-25.53

Competitors Valuation Multiple

The average P/S ratio for XERS's competitors is 20.43, providing a benchmark for relative valuation. Xeris Biopharma Holdings Inc Corp (XERS) exhibits a P/S ratio of 9.70, which is -52.51% above the industry average. Given its robust revenue growth of 48.84%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

XERS.O

Xeris Biopharma Holdings Inc

BioCryst Pharmaceuticals Inc

Stoke Therapeutics Inc

Abcellera Biologics Inc

Immunocore Holdings PLC

Sionna Therapeutics Inc

38.21

1.59B

Performance Decomposition

Market capitalization of XERS increased by 201.83% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -13.43 to -46.25.

The secondary factor is the Revenue Growth, contributed 48.84%to the performance.

Overall, the performance of XERS in the past 1 year is driven by P/E Change. Which is more unsustainable.

48.84%

48.07M → 71.54M

Revenue Growth

-91.35%

-31.22 → -2.70

Margin Expansion

244.34%

-13.43 → -46.25

P/E Change

201.83%